Heart and Lung Transplants from HCV-Infected Donors
To the Editor: Woolley et al. (April 25 issue) 1 report encouraging results of the Donors of Hepatitis C NAT [nucleic acid amplification test] Positive Thoracic Allografts for Transplantation Evaluation in Non-HCV Recipients (DONATE HCV) trial, which showed safety and efficacy of preemptive direct-a...
Gespeichert in:
Veröffentlicht in: | The New England journal of medicine 2019-09, Vol.381 (10), p.987-989 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | To the Editor:
Woolley et al. (April 25 issue)
1
report encouraging results of the Donors of Hepatitis C NAT [nucleic acid amplification test] Positive Thoracic Allografts for Transplantation Evaluation in Non-HCV Recipients (DONATE HCV) trial, which showed safety and efficacy of preemptive direct-acting antiviral therapy immediately after transplantation to treat hepatitis C virus (HCV)–negative lung-transplant and heart-transplant recipients who received grafts from donors with hepatitis C viremia. In the accompanying editorial,
2
there was concern regarding assurance of access to direct-acting antiviral therapy in advance of acceptance of a heart or lung from donors with hepatitis C viremia. Patients with Medicare . . . |
---|---|
ISSN: | 0028-4793 1533-4406 |
DOI: | 10.1056/NEJMc1907009 |